Monarch Alternative Capital LP Raised Spirit Realty Capital (SRC) Holding; Renaissance Group Has Cut Gilead Sciences (GILD) Position by $359,550; Share Price Declined

June 10, 2018 - By Kurt Siggers

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Renaissance Group Llc decreased its stake in Gilead Sciences (GILD) by 1.24% based on its latest 2018Q1 regulatory filing with the SEC. Renaissance Group Llc sold 4,794 shares as the company’s stock declined 17.62% with the market. The institutional investor held 382,337 shares of the health care company at the end of 2018Q1, valued at $28.82 million, down from 387,131 at the end of the previous reported quarter. Renaissance Group Llc who had been investing in Gilead Sciences for a number of months, seems to be less bullish one the $93.50B market cap company. The stock increased 0.01% or $0.01 during the last trading session, reaching $71.91. About 4.86 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 10, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 15/05/2018 – Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy; 05/03/2018 – GILEAD: BIKTARVY FOUND TO BE NON-INFERIOR TO ABACAVIR REGIMEN; 01/05/2018 – GILEAD CHIEF SCIENTIFIC OFFICER JOHN MCHUTCHISON SPEAKS ON CALL; 15/05/2018 – KITE ANNOUNCES NEW WORLDWIDE FACILITIES AND EXPANDED COLLABORATION WITH NATIONAL CANCER INSTITUTE TO SUPPORT CELL THERAPY PIPELINE; 25/04/2018 – GILEAD HAD BEEN SUED BY MERCK OVER ITS HEPATITIS DRUGS; 30/05/2018 – GALAPAGOS NV – IN TRIAL ONE OTHER PATIENT RECEIVING FILGOTINIB DEVELOPED HERPES ZOSTER; 16/03/2018 – Gilead TAF Sales Fall 3%, HIV Combo Pills Drop 3%; 31/05/2018 – ACR20 80 — not too shabby: Gilead and Galapagos bag promising PhII data for star immunology drug filgotinib – boosting late-stage focus $GILD $GLPG; 01/05/2018 – Gilead Sciences 1Q EPS $1.17; 30/05/2018 – GALAPAGOS NV – EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20 RESPONSE AT WEEK 16

Michael Weinstock increased its stake in Spirit Realty Capital Inc (SRC) by 186.93% based on its latest 2018Q1 regulatory filing with the SEC. Monarch Alternative Capital Lp bought 4.25 million shares as the company’s stock rose 11.35% while stock markets declined. The hedge fund run by Michael Weinstock held 6.52 million shares of the consumer services company at the end of 2018Q1, valued at $50.63 million, up from 2.27 million at the end of the previous reported quarter. Monarch Alternative Capital Lp who had been investing in Spirit Realty Capital Inc for a number of months, seems to be bullish on the $3.36B market cap company. It closed at $7.83 lastly. It is down 17.41% since June 10, 2017 and is uptrending. It has outperformed by 4.84% the S&P500. Some Historical SRC News: 01/05/2018 – Spirit Realty Capital 1Q Rev $165.3M; 21/03/2018 – SPIRIT REALTY CAPITAL – MOST RECENTLY, HUGHES WAS CFO AT FELCOR LODGING TRUST; 13/04/2018 – Spirit MTA REIT Publicly Files Amended Form 10 Registration Statement in Connection with Planned Spin-off from Spirit Realty Capital; 17/05/2018 – Spirit Realty Favored by 5 Hedge Funds, 13Fs Show; 13/04/2018 – Spirit MTA REIT Publicly Files Amended Form 10 Registration Statement in Connection with Planned Spin-off from Spirit Realty Ca; 04/05/2018 – Spirit MTA REIT Publicly Files Second Amendment to Form 10 Registration Statement in Connection with Planned Spin-off from Spirit Realty Capital; 21/03/2018 – SPIRIT REALTY CAPITAL, NAMES MICHAEL HUGHES AS CFO; 01/05/2018 – CORRECT: SPIRIT REALTY FY AFFO/SHR FORECAST REPORTED IN ERROR; 13/04/2018 – SPIRIT REALTY CAPITAL INC – UNIT PUBLICLY FILED WITH U.S. SEC AN AMENDED REGISTRATION STATEMENT ON FORM 10; 01/05/2018 – SPIRIT REALTY CAPITAL 1Q AFFO/SHR 22C EX-CASH SEVERANCE CHARGE

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “The Kite Killer – TapImmune And Marker Merger Challenges Gilead” on May 30, 2018, also Seekingalpha.com with their article: “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” published on May 15, 2018, Bizjournals.com published: “He helped Gilead score billions from HIV, hepatitis C drugs — now he’s building a cancer fighter” on May 23, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead’s Evolution In Oncology, With Comments On Valuation” published on June 07, 2018 as well as Bizjournals.com‘s news article titled: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” with publication date: May 17, 2018.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 25. They expect $1.42 EPS, down 43.43% or $1.09 from last year’s $2.51 per share. GILD’s profit will be $1.85 billion for 12.66 P/E if the $1.42 EPS becomes a reality. After $1.37 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 3.65% EPS growth.

Investors sentiment increased to 0.88 in 2018 Q1. Its up 0.08, from 0.8 in 2017Q4. It improved, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Hodges Cap Mgmt has invested 0.09% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Verition Fund Ltd Liability reported 8,357 shares. Moreover, Ltd Ca has 0.39% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Moreover, Lipe & Dalton has 2.73% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 50,560 shares. Plante Moran Financial Advsrs Ltd has invested 0.09% in Gilead Sciences, Inc. (NASDAQ:GILD). Hikari Limited holds 1.31% or 147,930 shares in its portfolio. Windward Com Ca has 40,503 shares for 0.44% of their portfolio. Deutsche Bancorp Ag reported 0.48% stake. Investec Asset Mgmt Ltd has 87,345 shares for 0.04% of their portfolio. Burney accumulated 0.23% or 48,727 shares. 3,370 are owned by Bluefin Trading Lc. 141,103 were accumulated by Denali Advsr Lc. Moors Cabot holds 0.23% or 22,858 shares in its portfolio. Focused Wealth Mgmt reported 24,031 shares. Perkins Coie Tru Com owns 540 shares or 0.02% of their US portfolio.

Renaissance Group Llc, which manages about $2.94 billion US Long portfolio, upped its stake in Sk Telecom Ltd (NYSE:SKM) by 54,961 shares to 705,916 shares, valued at $17.06 million in 2018Q1, according to the filing. It also increased its holding in Lukoil Pjsc by 7,461 shares in the quarter, for a total of 326,597 shares, and has risen its stake in Teck Resources Ltd (NYSE:TCK).

Since January 2, 2018, it had 0 insider purchases, and 23 selling transactions for $48.21 million activity. The insider Alton Gregg H sold 25,000 shares worth $2.09 million. On Thursday, February 1 MARTIN JOHN C sold $4.18 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 50,000 shares. Meyers James R also sold $8.02M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, January 16. 5,000 shares valued at $401,566 were sold by Washington Robin L on Wednesday, February 21. 60,000 shares were sold by WILSON GAYLE E, worth $4.68M.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Tuesday, July 25 with “Buy”. On Friday, January 26 the stock rating was upgraded by Jefferies to “Buy”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Neutral” rating by Atlantic Securities on Friday, December 18. The company was maintained on Monday, October 3 by RBC Capital Markets. The firm has “Hold” rating given on Friday, July 29 by Argus Research. Piper Jaffray maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, July 24 with “Overweight” rating. Bank of America upgraded the shares of GILD in report on Friday, January 15 to “Neutral” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Wednesday, August 31 by Jefferies. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, May 2. Oppenheimer initiated Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, October 4 with “Hold” rating.

Since March 6, 2018, it had 2 insider buys, and 0 sales for $259,899 activity. GILCHRIST RICHARD I bought $60,000 worth of stock.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Kurt Siggers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: